Showing results (91-100 of 225) with videos related to
Sort By:
Pageof 23
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinomaRoberto Iacovelli, Daniele Santini, Mimma Rizzo, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 2, 2019
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Matteo Brunelli, et al.Cancer Treatment Reviews|March 18, 2022
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinationsRoberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, et al.Expert Review of Anticancer Therapy|June 24, 2024
2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinomaViria Beccia, Daniela Arduini, Roberto Iacovelli, et al.Critical Reviews in Oncology/Hematology|June 20, 2015
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysisFilippo Pietrantonio, Chiara Cremolini, Fausto Petrelli, et al.Immunotherapy|June 10, 2017
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studiesChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.International Journal of Cancer|January 14, 2014
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trialsMatteo Santoni, Alessandro Conti, Francesco Massari, et al.Clinical Genitourinary Cancer|February 3, 2026
Clinical Outcomes of Targeted Therapies Following HIF-2α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World AnalysisPatricia Rioja, Macarena Rey-Cárdenas, Jorge Esteban-Villarrubia, et al.Cancer|June 27, 2013
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapiesSami Antoun, Emilie Lanoy, Roberto Iacovelli, et al.Oncotarget|October 10, 2015
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinomaFrancesco Piva, Matteo Giulietti, Giulia Occhipinti, et al.Pageof 23